Your AI-Trained Oncology Knowledge Connection!
Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.
An expert discussion on evolving first-line treatment strategies for newly diagnosed diffuse large B-cell lymphoma (DLBCL), incorporating insights from the 2024 NCCN guidelines, unmet needs in 1L therapies, and the impact of POLARIX trial updates on the use of Pola+R-CHP in clinical practice.
An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.
An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.
A concise discussion of second-line treatment strategies for DLBCL, highlighting preferred regimens for transplant-eligible and ineligible patients, as well as treatment approaches based on the timing of relapse.
A concise discussion of second-line treatment options for DLBCL, focusing on preferred regimens for transplant-eligible and ineligible patients, and tailored approaches based on relapse timing.
An analysis of key updates on CAR T-cell therapy in DLBCL from ZUMA-7 and TRANSFORM trials, exploring its potential as a primary second-line option, along with insights into efficacy and safety data for transplant-ineligible patients from ALYCANTE and PILOT studies
A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.
A review of real-world outcomes for CAR T-cell therapies in the relapsed/refractory setting from ASH 2024, comparing them to clinical trial results and addressing safety management concerns, toxicities, and prophylactic treatment options in practice.
An overview of challenges with CAR T-cell therapy, including combating T-cell exhaustion, the pros and cons of outpatient administration, logistical barriers, and the role of polatuzumab in bridging therapy, along with a discussion of non-cellular second-line options such as pola+BR and findings from L-MIND compared to real-world data
A discussion of current trials on bispecific antibody therapies in DLBCL, highlighting key takeaways from STARGLO on Glofit+GemOx in relapsed/refractory disease, the potential role of bispecifics in second-line treatment, and the patient populations and care settings most likely to benefit from these emerging options.
An overview of third-line treatment options for DLBCL, including choices for patients who did not receive CAR T-cell therapy or transplant in second-line, strategies for those who progress after CAR T-cell or transplant, and the impact of bispecific antibodies and ADCs, with insights from key studies on Glofit and Epcor in relapsed/refractory DLBCL and their implications for patient selection and care.
A discussion of major challenges in using bispecific antibodies in the relapsed/refractory DLBCL setting, focusing on dosing, safety concerns like CRS, and step-up dosing strategies, along with insights on best practices for community clinics; followed by a review of sequencing bispecific antibodies and CAR T-cell therapies in third-line treatment, informed by recent studies on bispecific/CAR T sequencing
A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year
